More tools:Markets·Screener·Research·Chat

10x Genomics, Inc. Class A Common Stock (TXG) Financial Statements

10x Genomics, Inc. Class A Common Stock
SIC 3826 · LABORATORY ANALYTICAL INSTRUMENTS
FIGI BBG007WX14Y9
XNAS · usd
65.60▲ 2.95 (4.71%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close62.65
Day's Range61.36 – 66.03
52-Week Range11.16 – 66.94
Volume3.3M
Avg Volume2.9M
Share Statistics
Shares Outstanding
Employees1,178
ExchangeXNAS
Listed2019-09-12
Share count as of July 31, 2026
Loading Income Statement…
Key questions about 10x Genomics, Inc. Class A Common Stock (TXG)
What is 10x Genomics, Inc. Class A Common Stock's Market Cap?
10x Genomics, Inc. Class A Common Stock's Market Cap is $8.5B, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's Enterprise Value?
10x Genomics, Inc. Class A Common Stock's Enterprise Value is $8.0B, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's Price / Sales?
10x Genomics, Inc. Class A Common Stock's Price / Sales is 13.9×, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's EV / Revenue?
10x Genomics, Inc. Class A Common Stock's EV / Revenue is 13.0×, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's EV / EBITDA?
10x Genomics, Inc. Class A Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's Revenue (TTM)?
10x Genomics, Inc. Class A Common Stock's Revenue (TTM) is $616.9M, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's Net Income (TTM)?
10x Genomics, Inc. Class A Common Stock's Net Income (TTM) is -$75.1M, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's EBITDA?
10x Genomics, Inc. Class A Common Stock's EBITDA is -$48.4M, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's Diluted EPS (TTM)?
10x Genomics, Inc. Class A Common Stock's Diluted EPS (TTM) is -0.58, based on as-reported figures from SEC (XBRL) filings.
What is 10x Genomics, Inc. Class A Common Stock's EBITDA Margin?
10x Genomics, Inc. Class A Common Stock's EBITDA Margin is -7.8%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-12.6%-2.6%+0.6%-1.7%
Cost of products and services revenue
Gross profit
% of revenue74.5%70.4%68.1%67.3%
Operating expenses:
Research and development
Selling, general and administrative
Gain on settlement
Total operating expenses
% of revenue87.4%81.7%79.9%89.0%
Income (loss) from operations
% of revenue-12.9%-11.3%-11.8%-21.6%
Other income (expense):
Interest income
Interest expense—
Other income (expense), net
Total other income
Income (loss) before provision for income taxes
Provision for (benefit from) income taxes
Net income (loss)
% of revenue-11.9%-8.9%-9.8%-18.4%
Net income (loss) per share, basic (in dollars per share)
Net income (loss) per share, diluted (in dollars per share)